Profilo
Dr. Marco Verwijs is an Executive Vice President-Technical Operations at CervoMed, Inc. Dr. Verwijs was previously employed as a Chief Technical Officer by Aerovate Therapeutics, Inc., a Chief Technical Officer by Adipo Therapeutics LLC, and a Chief Technology Officer by Aerovate Therapeutics, Inc. He received his graduate degree from Delft University of Technology and a doctorate degree from the University of Florida.
Posizioni attive di Marco Verwijs
| Società | Posizione | Inizio |
|---|---|---|
| CERVOMED INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2025 |
Precedenti posizioni note di Marco Verwijs
| Società | Posizione | Fine |
|---|---|---|
| JADE BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 01/07/2024 |
| JADE BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | - |
Adipo Therapeutics LLC
Adipo Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops polymer-based, notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Marco Verwijs
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
University of Florida
University of Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Delft University of Technology
Delft University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Adipo Therapeutics LLC
Adipo Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops polymer-based, notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue | Health Technology |
CervoMed, Inc.
CervoMed, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that develops novel therapies | Commercial Services |
















